ClinicalTrials.gg
CompletedNCT00813150Updated Aug 15, 2014Results posted

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

A Phase 3 interventional study of Dexamethasone and Bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag G.m.b.H. Completed at 40 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-15.

Sponsored by Janssen-Cilag G.m.b.H (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
81st of 373
96 · median 45
Started
2009
with 12 others
Phase 3
53 of 381
3 open now
Registered
84th of 381
by date

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 81st largest by enrollment of the 373 interventional ones that give a count, is one of 13 that started in 2009, is one of 53 in phase 3, and was the 84th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare bortezomib, dexamethasone and cyclophosphamide to bortezomib and dexamethasone alone for primary refractory or relapsed multiple myeloma.

Read the detailed description

This is a prospective, multi-centre, randomized (the study drug is assigned by chance), controlled, open-label (all people involved in the study know the identity of the assigned drug), parallel (each group of patients will be treated at the same time) group phase III study to determine the efficacy of the standard therapy of bortezomib and low dose dexamethasone in combination with or without continuous low dose oral cyclophosphamide for primary refractory or relapsed myeloma patients (1st - 3rd relapse). The study will consist of screening period, which may last from day -14 until day -1 before application of the first dose of bortezomib (on cycle 1, day 1), treatment phase begins on cycle 1 day 1 and continues until completion or discontinuation of all study drugs and follow-up phase. All patients will be followed up after end of treatment regardless of their response. Eligible patients will be randomized in 1:1 ratio to receive either treatment arms (Group A: receiving bortezomib plus dexamethasone or Group B receiving bortezomib plus dexamethasone plus cyclophosphamide). Patients will receive up to eight 3-weeks treatment cycles, unless they experience either unacceptable toxicity or if the patients request to withdraw from the study. The maximum number of cycles is dependent on patient response and investigator's discretion. It is recommended that patients with a confirmed complete response (CR) receive 2 additional cycles beyond a confirmation. Patients who do not achieve a CR but a partial response will receive a total of 8 cycles. For patients achieving stable disease it is within the investigator's discretion to continue study treatment beyond 6 cycles, after discussion with the sponsor. After completion of treatment the patients will be followed up every 12 weeks for up to 72 weeks. If the study is still ongoing a further follow up period will be done every 26 weeks until study end, or until the patient reaches progressive disease or start of alternative anti-myeloma therapy, if earlier. In case progressive disease (PD) has already been established during the treatment phase the patients will not enter the follow-up phase. In case of PD or start of alternative anti-myeloma treatment before the end of study the follow-up phase will be discontinued for the patient but the date of death of the patient will be documented (if applicable) before the end of study.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple myeloma
  • Bortezomib
  • Dexamethasone
  • Cyclophosphamide
  • Oncology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously diagnosed with multiple myeloma
  • Primary multiple myeloma or relapsed following 1 to 3
  • performance status must be equal to 60 percentage (ie, better or equal performance than requiring some help and taking care of most personal requirements)
  • Has estimated at screening must be of at least 6 months
  • Agrees to protocol-defined use of effective

Exclusion criteria

Exclusion Criteria:

  • Not received more than three for multiple myeloma
  • Not received nitrosoureas or any other chemotherapy or immunotherapy or antibody therapy for multiple myeloma within 6 to 8 weeks before enrolment. Plasmapheresis must not be applied within 2 weeks before enrolment
  • Patients with peripheral neuropathy or neuropathic pain of Grade 2 or greater intensity
  • Patients with poorly controlled cardio vascular, vascular, pulmonary, gastro-intestinal, endocrine, neurological, psychiatric, hepatic, renal or metabolic diseases or hematological disorders
  • Not have oligosecretory or non-secretory multiple myeloma
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Vd (bortezomib + dexamethasone)

    Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle.

    Drug: Dexamethasone · Drug: Bortezomib

  • Active comparator
    Vcd (bortezomib + low-dose dexamethasone + cyclophosphamide)

    Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle and single oral doses of 50 mg cyclophosphamide on a once daily basis from Day 1, Cycle 1 continuously until Day 21, Cycle 8.

    Drug: Dexamethasone · Drug: Bortezomib · Drug: Cyclophosphamide

Interventions

  • Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.

  • Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.

  • Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.

06

What researchers measure

Primary outcomes

  1. Time to Progression of Disease

    'Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of \>=25% from lowest level in Serum M-component or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]); Urine M component or (the absolute increase must be \>=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase \>10 mg/dL. Bone marrow plasma cell percentage \>=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.

    Time frame: From the date of randomization until the disease progression or participant's death from any cause whichever occurred first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as time from randomization to myeloma progression according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of ≥25 percent from lowest response level in Serum M-component and/or (the absolute increase must be ≥0.5 g/dL) Urine M-component and/or (the absolute increase must be ≥200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be ≥10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65mmol/L) that can be attributed solely to the plasma cell proliferative disorder. PFS included disease progression as well as death.

    Time frame: From the date of randomization until the disease progression or participant's death from any cause whichever occured first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication)

  2. Overall Survival (OS)

    Time interval in months time from randomisation to death from any cause.

    Time frame: From the date of randomization until Month 49

  3. Overall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria

    Percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) is reported in the below table. IMWG criteria- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescencec; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90%; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100mg per 24 hour.

    Time frame: Up to 46 days after last bortezomib dose, or as soon as possible after early discontinuation of study treatment or before start of alternative anti-myeloma therapy

07

Results

Posted Aug 15, 2014

Participant flow

The study was conducted between 23 December 2008 and 10 January 2013 and recruited patients from 42 study centers in Germany.

Treatment Period
Participant flow — Treatment Period
MilestoneVd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)
Started4647
Intent-to-treat participants4347
Completed1415
Not completed3232
Withdrew: Adverse event1615
Withdrew: Death20
Withdrew: Progressive disease10
Withdrew: Complete response01
Withdrew: Stable disease12
Withdrew: Protocol violation34
Withdrew: Withdrawal by subject53
Withdrew: Non compliance01
Withdrew: Reason not specified34
Withdrew: Data not available12
Long Term Follow-up
Participant flow — Long Term Follow-up
MilestoneVd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)
Started2631
Completed20
Not completed2431
Withdrew: Death04
Withdrew: Other03
Withdrew: Lost to follow-up20
Withdrew: Progression/relapse2224

Outcome measures

PrimaryTime to Progression of Disease

'Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of \>=25% from lowest level in Serum M-component or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]); Urine M component or (the absolute increase must be \>=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase \>10 mg/dL. Bone marrow plasma cell percentage \>=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.

Time frame:
From the date of randomization until the disease progression or participant's death from any cause whichever occurred first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication)
Reported as:
Median · Months
Time to Progression of Disease
MonthsVd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)
Time to Progression of Disease12.6 (9.83 to 14.43)9.9 (8.60 to 11.40)
Statistical analysis
  • Vd (Bortezomib + Dexamethasone) vs Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) · Regression, Cox · p = 0.196 · Hazard ratio (hr): 0.71 · 95% CI 0.43 to 1.19
SecondaryProgression-Free Survival (PFS)

PFS is defined as time from randomization to myeloma progression according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of ≥25 percent from lowest response level in Serum M-component and/or (the absolute increase must be ≥0.5 g/dL) Urine M-component and/or (the absolute increase must be ≥200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be ≥10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65mmol/L) that can be attributed solely to the plasma cell proliferative disorder. PFS included disease progression as well as death.

Time frame:
From the date of randomization until the disease progression or participant's death from any cause whichever occured first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsVd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)
Progression-Free Survival (PFS)12.6 (9.83 to 14.43)9.9 (8.60 to 11.40)
Statistical analysis
  • Vd (Bortezomib + Dexamethasone) vs Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) · Regression, Cox · p = 0.196 · Hazard ratio (hr): 0.71 · 95% CI 0.43 to 1.19
SecondaryOverall Survival (OS)

Time interval in months time from randomisation to death from any cause.

Time frame:
From the date of randomization until Month 49
Reported as:
Median · Months
Overall Survival (OS)
MonthsVd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)
Overall Survival (OS)NA (NA to NA)41.50 (24.87 to NA)
Statistical analysis
  • Vd (Bortezomib + Dexamethasone) vs Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) · Regression, Cox · p = 0.645 · Hazard ratio (hr): 0.85 · 95% CI 0.41 to 1.73
SecondaryOverall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria

Percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) is reported in the below table. IMWG criteria- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescencec; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90%; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100mg per 24 hour.

Time frame:
Up to 46 days after last bortezomib dose, or as soon as possible after early discontinuation of study treatment or before start of alternative anti-myeloma therapy
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria
Percentage of participantsVd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)
Overall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria74.4 (NA to NA)70.2
Statistical analysis
  • Vd (Bortezomib + Dexamethasone) vs Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) · Fisher Exact · p = 0.814

Adverse events

Collected over Approximately 5 years. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vd (Bortezomib + Dexamethasone)—15/46 (32.6%)43/46 (93.5%)
Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)—14/47 (29.8%)46/47 (97.9%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventVd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)
PneumoniaInfections and infestations4/464/47
Multiple myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/460/47
DiverticulitisInfections and infestations2/460/47
SepsisInfections and infestations2/460/47
DyspnoeaRespiratory, thoracic and mediastinal disorders2/461/47
SyncopeNervous system disorders0/462/47
InfectionInfections and infestations1/460/47
ConstipationGastrointestinal disorders1/461/47
Ileus paralyticGastrointestinal disorders1/460/47
Inguinal hernia, obstructiveGastrointestinal disorders1/460/47
Most frequent other events
Showing 10 of 178
Most frequent other events
EventVd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)
ThrombocytopeniaBlood and lymphatic system disorders17/4618/47
FatigueGeneral disorders13/4618/47
DiarrhoeaGastrointestinal disorders11/4617/47
ConstipationGastrointestinal disorders10/4613/47
AnaemiaBlood and lymphatic system disorders12/466/47
NauseaGastrointestinal disorders7/4611/47
NasopharyngitisInfections and infestations3/4611/47
Oedema peripheralGeneral disorders7/4610/47
PolyneuropathyNervous system disorders7/469/47
Peripheral sensory neuropathyNervous system disorders3/469/47

Baseline characteristics

Number of Intent-to-treat (ITT) participants were included in Baseline analysis. Out of 93 randomized participants (Vd=46; Vcd=47), follow-up data on treatment response was not available for 3 participants, so, they were excluded from the Intent-to-treat (ITT) analysis data set and so, ITT included 90 participants (Vd=43; Vcd=47).

Age, Continuous
Age, Continuous(Years)Vd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)Total
Mean68 ± 1071 ± 769 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Vd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)Total
Female182139
Male252651
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vd (Bortezomib + Dexamethasone)Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide)Total
Caucasian424789
African101
08

Study locations

40 sites
  • Augsburg, Germany
  • Berlin, Germany
  • Bielefeld, Germany
  • Bremerhaven, Germany
  • Darmstadt, Germany
  • Donauwörth, Germany
  • Dresden, Germany
  • Frankfurt, Germany
  • Halle, Germany
  • Hamburg, Germany
  • Hamm, Germany
  • Hannover, Germany
  • Hildesheim, Germany
  • Hof, Germany
  • Koblenz, Germany
  • Köln, Germany
  • Lebach, Germany
  • Leer, Germany
  • Lübeck, Germany
  • Magdeburg, Germany
  • Mannheim, Germany
  • Moers, Germany
  • München, Germany
  • Münster, Germany
  • Neunkirchen, Germany
  • Offenburg, Germany
  • Oldenburg, Germany
  • Osnabrück, Germany
  • Passau, Germany
  • Porta Westfalica, Germany
  • Ravensburg, Germany
  • Rostock, Germany
  • Saarbrücken, Germany
  • Singen, Germany
  • Stuttgart, Germany
  • Velbert, Germany
  • Weiden, Germany
  • Wiesbaden, Germany
  • Würselen, Germany
  • Würzburg, Germany
09

References and documents

Publications

  • Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. doi: 10.1007/s00277-017-3065-z. Epub 2017 Sep 14. PubMed 28905189 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2008
First posted
Dec 22, 2008
Start
Jan 2009
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Aug 15, 2014
Last update
Aug 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00813150
Responsible party
Sponsor
First posted
Dec 22, 2008
Start date
Jan 2009
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Aug 15, 2014
Last update
Aug 15, 2014

Study contacts

Janssen-Cilag G.m.b.H, Germany Clinical Trial
study director · Janssen-Cilag G.m.b.H

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Bortezomib

Start the discussion